Blair William & Co. IL Sells 105,569 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Key Points

• Blair William & Co. IL reduced its position in TransMedics Group by 58.5%, selling over 105,000 shares during the first quarter, while still holding nearly 75,000 shares worth approximately $5 million.
• TransMedics Group reported $0.92 earnings per share for the last quarter, significantly exceeding analyst estimates of $0.48, with a revenue increase of 37.7% year-over-year.
• Multiple analysts have upgraded their ratings and price targets for TransMedics Group, with current consensus and price target reflecting a Moderate Buy rating and an average target price of $123.00.

Blair William & Co. IL cut its holdings in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 58.5% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 74,995 shares of the company's stock after selling 105,569 shares during the period. Blair William & Co. IL owned 0.22% of TransMedics Group worth $5,046,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the business. CWM LLC lifted its holdings in TransMedics Group by 20.1% in the 1st quarter. CWM LLC now owns 925 shares of the company's stock worth $62,000 after purchasing an additional 155 shares in the last quarter. Campbell Newman Asset Management Inc. lifted its holdings in TransMedics Group by 1.4% in the 1st quarter. Campbell Newman Asset Management Inc. now owns 11,619 shares of the company's stock worth $782,000 after purchasing an additional 166 shares in the last quarter. Hager Investment Management Services LLC lifted its holdings in TransMedics Group by 38.3% in the 1st quarter. Hager Investment Management Services LLC now owns 740 shares of the company's stock worth $50,000 after purchasing an additional 205 shares in the last quarter. Nisa Investment Advisors LLC lifted its holdings in TransMedics Group by 1.6% in the 1st quarter. Nisa Investment Advisors LLC now owns 15,824 shares of the company's stock worth $1,065,000 after purchasing an additional 256 shares in the last quarter. Finally, PNC Financial Services Group Inc. lifted its holdings in TransMedics Group by 13.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 2,294 shares of the company's stock worth $154,000 after purchasing an additional 278 shares in the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. Oppenheimer boosted their price target on TransMedics Group from $130.00 to $150.00 and gave the stock an "outperform" rating in a report on Tuesday, June 17th. Wall Street Zen raised TransMedics Group from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Canaccord Genuity Group upped their price objective on TransMedics Group from $129.00 to $142.00 and gave the stock a "buy" rating in a report on Tuesday, July 15th. Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a report on Tuesday, June 17th. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $145.00 price objective (up from $125.00) on shares of TransMedics Group in a report on Wednesday, June 4th. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, TransMedics Group has an average rating of "Moderate Buy" and a consensus target price of $123.00.

TransMedics Group Trading Down 2.3%

NASDAQ:TMDX traded down $2.75 during midday trading on Thursday, hitting $116.05. 869,973 shares of the company traded hands, compared to its average volume of 1,392,698. The firm's fifty day moving average is $124.11 and its 200-day moving average is $96.77. TransMedics Group, Inc. has a 12-month low of $55.00 and a 12-month high of $177.37. The firm has a market capitalization of $3.96 billion, a P/E ratio of 60.13 and a beta of 2.09. The company has a current ratio of 9.86, a quick ratio of 9.17 and a debt-to-equity ratio of 1.61.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.44. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%. The company had revenue of $157.37 million for the quarter, compared to analyst estimates of $146.64 million. During the same quarter in the prior year, the firm posted $0.35 EPS. TransMedics Group's quarterly revenue was up 37.7% compared to the same quarter last year. On average, sell-side analysts predict that TransMedics Group, Inc. will post 1 EPS for the current year.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, Director David Weill sold 732 shares of the company's stock in a transaction on Friday, May 23rd. The stock was sold at an average price of $123.88, for a total value of $90,680.16. Following the transaction, the director owned 12,134 shares of the company's stock, valued at $1,503,159.92. This represents a 5.69% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Anil P. Ranganath sold 686 shares of the company's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $139.80, for a total value of $95,902.80. Following the completion of the transaction, the insider directly owned 13,955 shares in the company, valued at $1,950,909. This trade represents a 4.69% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 12,418 shares of company stock valued at $1,512,613 in the last quarter. 7.00% of the stock is owned by insiders.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.